RenoVate Therapeutics is an early-stage biotechnology company based on the research conducted by Prof. Benjamin Dekel, Head of the Pediatric Stem cell Research Institute and the Director of the Division of Pediatric Nephrology at Sheba Medical Center, Israel. RenoVate is developing regenerative biomolecules aimed to repair and rejuvenate kidneys. The regenerative biomolecules are derived from cells expanded from a patient’s own urine using proprietary technology. This groundbreaking IP will ultimately prevent the need for dialysis and kidney transplantations.
Menu
